item management s discussion and analysis of financial condition and results of operations the following discussion and analysis should be read in conjunction with selected consolidated financial data and the company s consolidated financial statements and notes thereto included elsewhere in this report 
in addition to the historical information contained herein  the discussions in this report may contain forward looking statements that involve risks and uncertainties 
the company s actual results could differ materially from those discussed herein 
overview the company provides a broad range of value added products and services focused on chemical analysis to the worldwide pharmaceutical  medical device and biotechnology industries 
the company s customer focused approach and high quality products and services enable it to serve as a value added partner in solving complex scientific problems by providing cost effective results to its customers on an accelerated basis 
founded in in lansing  michigan and relocated to west lafayette  indiana in  the company has experienced growth primarily through internal expansion  supplemented by strategic acquisitions 
as part of its internal growth strategy  the company has developed technical specialties in such areas as chromatography  electrochemistry  in vivo sampling and mass spectrometry 
the company s growth has strategically positioned it to take advantage of globalization in the marketplace and to provide new services and areas of technical expertise to its customers 
during this phase  the company has been continuously profitable since throughout its history  the company has taken steps to position itself as a global leader in the analytical chemistry field 
development of the company s infrastructure began in when it established relationships with several customers and multiple international distributors 
in  the company increased its sphere of influence to include japan with the creation of bas japan  an independent distributor 
in  the company enhanced its computer software expertise by acquiring interactive microware  inc in  the company began offering contract services to customers that lacked the time or expertise to perform certain analyses using the company s analytical products 
in  the company acquired a distributor  bas technicol ltd  to further solidify its presence in the united kingdom 
revenues are derived principally from i the sale of the company s analytical instruments and other products  and ii analytical services provided to customers 
both methods of generating revenue utilize the company s ability to identify  isolate and resolve client problems relating to the separation and quantification of individual substances in complex mixtures 
the company s analytical products are sold primarily to pharmaceutical firms and research organizations 
the company supports the pharmaceutical industry by focusing on analytical chemistry for biomedical research  diagnostics  electrochemistry and separations science 
principal customers include scientists engaged in drug metabolism studies  as well as those engaged in basic neuroscience research 
the company was the first to commercialize the liquid chromatograph and electrochemistry technology which is now considered the worldwide standard for the determination of neurotransmitter substances 
research products include in vivo sampling devices  reagent chemicals  electrochemical apparatus and sensors 
revenue from the sale of the company s products and the related costs are recognized upon shipment of the products to customers 
the company s pharmaceutical service contracts generally have terms ranging from several months to several years 
a portion of the contract fee is generally payable upon receipt of the initial samples with the balance payable in installments over the life of the contract 
the contracts are broken down into discrete units of deliverable services for which a fixed fee per unit is established 
revenue and related direct costs are recognized as specific contract terms are fulfilled under the percentage of completion method utilizing units of delivery 
the termination of a contract results in no material adjustments to revenue or direct costs previously recognized 
the company is entitled to payment for all work performed through the date of notice of termination and all costs associated with termination of a contract 
the company s management believes that fluctuations in the company s quarterly results are caused by a number of factors  including the company s success in attracting new business  the size and duration of service contracts  the timing of its clients decisions to enter into new contracts  the cancellation or delays of on going contracts  the timing of acquisitions and other factors  many of which are beyond the company s control 
in fiscal  approximately of the company s total revenue was derived from customers located outside the united states 
these markets tend to be much more volatile than the united states market 
significant governmental  regulatory  political  economic and cultural issues or changes could adversely affect the growth or profitability of the company s business activities in any such market 
results of operations the following table sets forth  for the periods indicated  certain statement of income data as a percentage of total revenue 
percentage of revenue percentage of revenue percentage of revenue year ended year ended year ended september  september  september  product revenue services revenue total revenue cost of product revenue cost of services revenue total cost of revenue gross profit operating expenses selling research and development general and administrative total operating expenses operating income other income expense  net income before income taxes income taxes net income 
remainder of page intentionally left blank 
year ended september  compared with year ended september  total revenue for the year ended september  increased to approximately million from approximately million in the year ended september  the net increase of approximately million related primarily to increased revenue from services  which increased to approximately million in the year ended september  from approximately million in the year ended september  as a result of the expansion of the types and volume of services provided by the company 
during this same period  product revenue increased to approximately million for the year ended september  from approximately million for the year ended september  primarily as a result of increased penetration in the physiology and the liquid chromatography markets 
costs of revenue increased to approximately million for the year ended september  from approximately million for the year ended september  this increase of approximately million was largely due to the hiring of additional support staff in the services unit 
costs of revenue for the company s products increased to as a percentage of product revenue for the year ended september  from of product revenue for the year ended september   due primarily to a change in product mix 
costs of revenue for the company s services increased to approximately as a percentage of services revenue for the year ended september  from approximately of services revenue for the year ended september  due to an increase in services support staff 
selling expenses for the year ended september  increased to approximately million from approximately million during the year ended september  due to increased salary expense 
research and development expenses for the year ended september  increased to approximately million from approximately million for the year ended september  due to the increase in research grant activity 
general and administrative expenses for the year ended september  increased to approximately million from approximately million for the year ended september   primarily as a result of increased legal expenses associated with the patent infringement suit 
see item legal proceedings other income expense  net  was approximately  in the year ended september  as compared to approximately  in the year ended september  as a result of the increase in interest income due to an increase in cash and cash equivalents resulting from the initial public offering 
the company s effective tax rate for was as compared to for fiscal this increase was primarily due to nondeductible foreign losses incurred in fiscal year ended september  compared with year ended september  total revenue for the year ended september  increased to approximately million from approximately million in the year ended september  the net increase of approximately million related primarily to increased revenue from services  which increased to approximately million in the year ended september  from approximately million in the year ended september  as a result of the expansion of types and volume of services provided by the company 
during this same period  product revenue increased to approximately million for the year ended september  from approximately million for the year ended september  primarily as a result of increased penetration in the electrochemistry and the liquid chromatography markets 
costs of revenue increased to approximately million for the year ended september  from approximately million for the year ended september  this increase of approximately  was largely due to the hiring of additional support staff in the services unit 
costs of revenue for the company s products decreased to as a percentage of product revenue for the year ended september  from of product revenue for the year ended september   due to a change in product mix 
costs of revenue for the company s services increased to approximately as a percentage of services revenue for the year ended september  from approximately of services revenue for the year ended september  due to an increase in services support staff 
selling expenses for the year ended september  increased to approximately million from approximately million during the year ended september  due to increased commissions on foreign sales 
research and development expenses for the year ended september  increased to approximately million from approximately million for the year ended september  due to the development of the in vivo product line 
general and administrative expenses for the year ended september  increased to approximately million from approximately million for the year ended september   primarily as a result of increased property taxes incurred in connection with the company s purchase and construction of additional facilities 
other income expense  net  was approximately  in the year ended september  as compared to approximately  in the year ended september  as a result of a reduction of interest income due to a reduction in cash and cash equivalents resulting from the redemption of redeemable preferred shares owned by the company s venture capital shareholders in accordance with their terms 
the company s effective tax rate for was as compared to for fiscal this decrease was primarily due to utilization of the research and development tax credit 
liquidity and capital resources since its inception  the company s principal sources of cash have been cash flow generated from operations and funds received from bank borrowings and other financings including the company s initial public offering which was completed in november at september   the company had cash and cash equivalents of approximately million  compared to cash and cash equivalents of approximately  at september  the increase in cash resulted primarily from the initial public offering which funded the increase in capital expenditures made to expand the company s facilities and operations 
the company s net cash provided by operating activities was approximately million for the year ended september  cash provided by operations during the year ended september  consisted of net income of approximately  plus non cash charges of approximately  plus a net decrease of approximately  in operating assets and liabilities 
the most significant decrease in operating assets related to trade accounts receivable  which decreased approximately  at september  cash used by investing activities increased to approximately million for the year ended september  from approximately million for the year ended september   primarily as a result of the company s purchase and construction of additional facilities  as well as the acquisition of clinical innovations 
cash provided by financing activities for fiscal was approximately million due to the initial public offering partially offset by the reduction of debt 
the company s net cash provided by operating activities was approximately  for the year ended september  cash provided by operations during the year ended september  consisted of net income of approximately  plus non cash charges of approximately  partially offset by a net increase of approximately  in operating assets and liabilities 
the most significant increase in operating assets related to accounts receivable  which increased to approximately million at september  from approximately million at september   due primarily to sales growth 
cash used by investing activities increased to approximately million for the year ended september  from approximately million for the year ended september   primarily as a result of the company s purchase and construction of additional facilities 
cash provided by financing activities for fiscal was approximately million due to an increase in the company s long and short term debt and offset by the redemption of redeemable preferred shares in accordance with their terms 
total expenditures by the company for property and equipment were approximately million  million and million in fiscal  and  respectively 
expenditures made in connection with the expansion of the company s operating facilities and purchases of laboratory equipment account for the largest portions of these expenditures 
the company anticipates increased levels of capital expenditures in fiscal the increased capital investments relate to the completion of the renovation and construction of additional facilities and the purchase of additional laboratory equipment corresponding to anticipated increases in research services to be provided by the company 
the company also completed two acquisitions during fiscal net payments made in connection with these acquisitions were approximately million 
the company expects to make other investments to expand its operations through internal growth  strategic acquisitions  alliances and joint ventures 
however  the company currently has no firm commitments for capital expenditures other than in connection with the expansion of the company s facilities 
based on its current business activities  the company believes that cash generated from its operations  amounts available under its existing bank lines of credit and credit facility and the remaining net proceeds from its initial public offering will be sufficient to fund the company s working capital and capital expenditure requirements for the foreseeable future 
the company has a million bank line of credit agreement which expires march  interest is charged at the prime rate at september  
at september   the line was unused 
the line is collateralized by inventories and accounts receivable 
all prior year bank debt obligations were repaid in full on november  using the proceeds received from the company s initial public offering 
inflation to date  the company believes that the effects of inflation have not had a material adverse effect on its business  operations or financial condition 
year the company undertook in fiscal to identify those information technology and other systems which may not be year compliant 
the company has identified that its primary computer hardware and software systems will require modifications  and the company has developed and commenced implementation of a plan to modify such systems to recognize the year management currently expects this project to be substantially complete by the spring of  and management estimates that the project will involve capital expenditures excluding normal system upgrades and replacements of less than  management has initiated discussions with significant suppliers  customers and financial institutions to ensure that those parties have appropriate plans to remediate year issues where their systems interface with the company s systems or otherwise impact its operations 
the company is also assessing the extent to which its operations are vulnerable should those organizations fail to properly remediate their computer systems 
the cost of the year initiatives in the aggregate is not expected to be material to the company s results of operations or financial position 
new accounting pronouncements in july  the financial accounting standards board the fasb issued statement no 
sfas  disclosures about segments of an enterprise and related information 
under sfas  the company will report financial and descriptive information about its operating segments 
sfas is effective for fiscal years beginning after december  the company plans to adopt sfas on october  the company has not yet evaluated the impact of sfas in june  the fasb issued statement of financial accounting standards no 
sfas  reporting comprehensive income 
sfas establishes standards for the reporting and display of comprehensive income in financial statements 
sfas is effective for fiscal years beginning after december  the company plans to adopt sfas on october  the company has not yet evaluated the impact of sfas item a 
quantitative and qualitative disclosures about market risk not applicable 

